Logo Logo
Eine Ebene nach oben
Exportieren als [RSS feed] RSS 1.0 [RSS2 feed] RSS 2.0
Gruppiert nach: Dokumententyp | Veröffentlichungsdatum
Anzahl der Publikationen: 6

Zeitschriftenartikel

Oliu-Barton, Miquel; Pradelski, Bary S. R.; Algan, Yann; Baker, Michael G.; Binagwaho, Agnes; Dore, Gregory J.; El-Mohandes, Ayman; Fontanet, Arnaud; Peichl, Andreas; Priesemann, Viola; Wolff, Guntram B.; Yamey, Gavin und Lazarus, Jeffrey (2021): Elimination versus mitigation of SARS-CoV-2 in the presence of effective vaccines. In: Lancet Global Health, Bd. 10, Nr. 1, E142-E147

Marshall, Alison D.; Cunningham, Evan B.; Nielsen, Stine; Aghemo, Alessio; Alho, Hannu; Backmund, Markus; Bruggmann, Philip; Dalgard, Olav; Seguin-Devaux, Carole; Flisiak, Robert; Foster, Graham R.; Gheorghe, Liana; Goldberg, David; Goulis, Ioannis; Hickman, Matthew; Hoffmann, Patrick; Jancoriene, Ligita; Jarcuska, Peter; Kaberg, Martin; Kostrikis, Leondios G.; Makara, Mihaly; Maimets, Matti; Marinho, Rui Tato; Maticic, Mojca; Norris, Suzanne; Olafsson, Sigurour; Ovrehus, Anne; Pawlotsky, Jean-Michel; Pocock, James; Robaeys, Geert; Roncero, Carlos; Simonova, Marieta; Sperl, Jan; Tait, Michele; Tolmane, Ieva; Tomaselli, Stefan; Valk, Marc van der; Vince, Adriana; Dore, Gregory J.; Lazarus, Jeffrey V. und Grebely, Jason (2018): Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. In: Lancet Gastroenterology & Hepatology, Bd. 3, Nr. 2: S. 125-133

Grebely, Jason; Dalgard, Olav; Cunningham, Evan B.; Hajarizadeh, Behzad; Foster, Graham R.; Bruggmann, Philip; Conway, Brian; Backmund, Markus; Robaeys, Geert; Swan, Tracy; Amin, Janaki; Marks, Philippa S.; Quiene, Sophie; Applegate, Tanya L.; Weltman, Martin; Shaw, David; Dunlop, Adrian; Hellard, Margaret; Bruneau, Julie; Midgard, Havard; Bourgeois, Stefan; Stähelin, Cornelia und Dore, Gregory J. (2017): Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. In: International Journal of Drug Policy, Bd. 47: S. 177-186

Midgard, Havard; Hajarizadeh, Behzad; Cunningham, Evan B.; Conway, Brian; Backmund, Markus; Bruggmann, Philip; Bruneau, Julie; Bourgeois, Stefan; Dunlop, Adrian; Foster, Graham R.; Hellard, Margaret; Robaeys, Geert; Thurnheer, Maria C.; Weltman, Martin; Amin, Janaki; Marks, Philippa S.; Quiene, Sophie; Dore, Gregory J.; Dalgard, Olav und Grebely, Jason (2017): Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. In: International Journal of Drug Policy, Bd. 47: S. 230-238

Cunningham, Evan B.; Hajarizadeh, Behzad; Dalgard, Olav; Amin, Janaki; Hellard, Margaret; Foster, Graham R.; Bruggmann, Philip; Conway, Brian; Backmund, Markus; Robaeys, Geert; Swan, Tracy; Marks, Philippa S.; Quiene, Sophie; Applegate, Tanya L.; Weltman, Martin; Shaw, David; Dunlop, Adrian; Bruneau, Julie; Midgard, Havard; Bourgeois, Stefan; Thurnheer, Maria Christine; Dore, Gregory J. und Grebely, Jason (2017): Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. In: BMC infectious Diseases 17:420 [PDF, 646kB]

Grebely, Jason; Swan, Tracy; Hickman, Matthew; Bruneau, Julie; Bruggmann, Philip; Dalgard, Olav; Litwin, Alain; Backmund, Markus und Dore, Gregory J. (2017): Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C. In: Journal of Hepatology, Bd. 66, Nr. 5: S. 1101-1103

Diese Liste wurde am Sat Mar 23 23:54:47 2024 CET erstellt.